What is Wedbush's Forecast for Nuvation Bio FY2028 Earnings?

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Equities research analysts at Wedbush issued their FY2028 earnings per share (EPS) estimates for shares of Nuvation Bio in a research note issued to investors on Tuesday, October 22nd. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.01) for the year. Wedbush has a "Outperform" rating and a $5.00 price objective on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.40) per share.

Several other brokerages have also weighed in on NUVB. Royal Bank of Canada reissued an "outperform" rating and set a $5.00 target price on shares of Nuvation Bio in a research report on Tuesday, August 6th. HC Wainwright lowered their target price on shares of Nuvation Bio from $8.00 to $7.00 and set a "buy" rating for the company in a report on Monday, September 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $6.40.

Nuvation Bio Trading Down 3.3 %

Shares of NUVB stock traded down $0.08 on Wednesday, reaching $2.33. 1,096,648 shares of the stock were exchanged, compared to its average volume of 1,425,511. The company has a market capitalization of $580.73 million, a price-to-earnings ratio of -1.11 and a beta of 1.36. The business's 50 day moving average price is $2.70 and its 200 day moving average price is $2.95. Nuvation Bio has a twelve month low of $0.95 and a twelve month high of $4.16.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The business had revenue of $1.44 million for the quarter.

Insider Buying and Selling at Nuvation Bio

In other Nuvation Bio news, Director Robert Mashal purchased 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 8th. The stock was purchased at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the purchase, the director now directly owns 100,000 shares in the company, valued at approximately $220,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nuvation Bio

Several large investors have recently modified their holdings of NUVB. B. Riley Wealth Advisors Inc. purchased a new stake in Nuvation Bio in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its stake in shares of Nuvation Bio by 913.2% in the second quarter. EverSource Wealth Advisors LLC now owns 11,095 shares of the company's stock valued at $32,000 after buying an additional 10,000 shares in the last quarter. Xponance Inc. acquired a new position in Nuvation Bio during the second quarter worth $33,000. Caxton Associates LP purchased a new position in Nuvation Bio in the second quarter worth $43,000. Finally, Choreo LLC acquired a new stake in Nuvation Bio in the second quarter valued at $47,000. Hedge funds and other institutional investors own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.